FDA Approves Xocova as Pharmaceutical Industry Sees New Mergers and Licensing Deals

The U.S. Food and Drug Administration (FDA) has granted approval for Shionogi’s antiviral medication, Xocova, while the pharmaceutical industry reports several significant mergers, acquisitions, and licensing agreements. Additionally, industry analysts are currently examining the regulatory challenges that frequently prevent cell and gene therapies from reaching the market.

The recent business activity includes Servier’s acquisition of Edgewise Therapeutics, a move focused on the development of treatments for muscular dystrophy. Simultaneously, Eli Lilly has secured a licensing agreement for a long-acting GLP-2 therapy developed by Hanmi. The sector also saw a corporate merger between Rallybio and Avenzo Therapeutics. Amidst these developments, industry observer Sean Werner has published an analysis regarding the high failure rate of breakthrough cell and gene therapies during the final stages of the regulatory approval process.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI